Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613402 | 0.95 | MDM4 (0.61) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29366757 | 0.95 | MDM4 (0.61) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29352409 | 0.95 | MDM4 (0.61) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL1486216 | 0.95 | MDM4 (0.61) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29907974 | 0.95 | MDM4 (0.61) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL118370 | 0.95 | MDM4 (0.61) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30977677 | 0.95 | MDM4 (0.61) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL12537019 | 0.95 | MDM4 (0.61) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30080650 | 0.93 | MDM4 (0.53) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29451083 | 0.93 | CASP3 (0.59) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249808-B | CAGRILINTIDE synthesis method | 江苏诺泰澳赛诺生物制药股份有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | claimed |
| EP-4736946-A2 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736945-A2 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| CN-119350469-B | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119661685-A | Canagliflozin peptide synthesis method | 杭州思诺达医药科技有限责任公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250064895-A1 | AMYLIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2025-02-27 | — | — | US | disclosed |
| CN-119350469-A | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-114249808-B | CAGRILINTIDE synthesis method | 江苏诺泰澳赛诺生物制药股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114249808-B | CAGRILINTIDE synthesis method | 江苏诺泰澳赛诺生物制药股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-12083164-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2024-09-10 | — | — | US | disclosed |
| CN-117986347-A | Synthesis method of canagliptin | 杭州思诺达医药科技有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117586336-A | Synthesis method and application of difficult polypeptide | 山东大学 | 2024-02-23 | — | — | CN | disclosed |
| EP-4074729-A1 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2022-10-19 | — | — | EP | disclosed |
| US-11382956-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2022-07-12 | — | — | US | disclosed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083164-B2 | Amylin analogues | IAPP, GLP1R, AMY2A | MDM4 3235/4885TP53 3331/4885CASP3 2209/4885 |
| US-20250064895-A1 | AMYLIN ANALOGUES | IAPP, GLP1R, AMY2A | MDM4 3235/4885TP53 3331/4885CASP3 2209/4885 |
| US-11382956-B2 | Amylin analogues | IAPP, GLP1R, AMY2A | MDM4 3235/4885TP53 3331/4885CASP3 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.